Carbamazepine became one of the defining antiseizure medicines of the second half of the twentieth century, but it was not originally developed as an epilepsy drug. Its story shows how medicinal chemistry, clinical observation and changing seizure classification came together.
A medicine that began somewhere else
Carbamazepine was synthesised in 1953 at J. R. Geigy in Switzerland during work on tricyclic compounds related to emerging psychiatric medicines. It was developed first for trigeminal neuralgia, and its antiseizure value was recognised later.
That sequence matters historically. Earlier antiseizure treatments were often discovered through sedation or serendipity; carbamazepine belongs to a transitional era in which pharmaceutical chemistry was becoming increasingly systematic.
Why it mattered for focal epilepsy
Carbamazepine became particularly important for focal seizures and focal-to-bilateral tonic-clonic seizures. Its success reinforced the idea that antiseizure medicines were not interchangeable and that seizure type should influence treatment choice.
What later research added
Clinical use revealed important limitations including dose-related neurological effects, hyponatraemia, hepatic enzyme induction and drug interactions. Rare serious skin reactions also led to one of epilepsy medicine’s clearest examples of pharmacogenetics, with HLA-B*15:02 testing relevant in some populations.
A turning point
Carbamazepine was neither an old sedative found by chance nor a modern target-designed molecule. It emerged from medicinal chemistry, found a first major role outside epilepsy, and then became a cornerstone of focal-seizure treatment.
Related reading
Sources and further reading
- Highlights in the history of epilepsy: the last 200 years
- Development of antiepileptic drugs throughout history
- Brief history of anti-seizure drug development
Evidence checked: September 2026.